Ethypharm acquires DB Ashbourne in the UK
Acquisition will generate a turnover of more than €240m for Ethypharm
Ethypharm has acquired 100% of the share capital of DBA Group, a branded pharmaceutical business established in the UK in 2009. DBA currently markets and supplies a range of prescription-only medicines to the UK market, and has an exciting pipeline of products in development, which will be supplemented with a wide range of additional products from Ethypharm.
With the acquisition of DBA, Ethypharm continues to implement its strategy to develop a direct commercial presence in key territories in Europe to market central nervous system products, with a particular focus on pain and innovative treatments for addiction. DBA provides a pivotal platform to generate revenues in the important UK market and this acquisition, along with the deployment of its own commercial operations in France and Germany, will generate a turnover of more than €240m for Ethypharm.
‘I am delighted to welcome the DBA team to the Ethypharm group. The acquisition of DBA is a significant step forward for us. The know-how and expertise of both companies are totally complementary and synergistic, and DBA offers a great platform to launch products from our own pipeline,’ said Hugues Lecat, CEO of Ethypharm.